SHERBORN, MA, CXL Ophthalmics, a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced it has raised a $32 million Series A funding round.
CXL Ophthalmics, a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced it has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists.
The new investments will support the advancement of CXL Ophthalmics' (CXLO) transformative cross-linking system, EpiSmart, through Phase 3 trials on the way to a New Drug Application with FDA.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
